French Pharma Stock News

LVMH Moët Hennessy - Louis Vuitton Société Européenne (ENXTPA:MC) has reshuffled its senior leadership, with Véronique Courtois and Antoine Arnault joining the group executive committee, a move that could influence how investors think about long term governance. See our latest analysis for LVMH Moët Hennessy - Louis Vuitton Société Européenne. These leadership changes come after a period where momentum has softened, with a 30 day share price return showing a 14.92% decline and a year to date...

BNP Paribas (ENXTPA:BNP) has been active on several fronts recently, with new moves in private debt, Japanese logistics real estate, battery energy storage, and SME financing, giving investors fresh information to assess the stock. See our latest analysis for BNP Paribas. At a share price of €90.84, BNP Paribas has a 90 day share price return of 36.21% and a 1 year total shareholder return of 43.17%. This suggests momentum has picked up recently after a softer 7 day share price move, as...

Hermès International Société en commandite par actions ( EPA:RMS ) came out with its full-year results last week, and...

Crédit Agricole (ENXTPA:ACA) has drawn fresh attention after releasing its fourth quarter and full year 2025 results, along with a proposed 2025 dividend of €1.13 per share, with payment scheduled for 28 May 2026. See our latest analysis for Crédit Agricole. At a share price of €18.03, Crédit Agricole has a 90 day share price return of 13.51%, while its 1 year total shareholder return of 25.56% and 5 year total shareholder return of 131.50% point to momentum that has been building over...

Rémy Cointreau (ENXTPA:RCO) is in focus after Rémy Martin introduced two V.S.O.P This Is My City limited edition bottles for Miami and Los Angeles, paired with $20,000 microgrants and mentorship for local creatives. See our latest analysis for Rémy Cointreau. These city focused releases arrive as the share price has gained momentum in the short term, with a 1 month share price return of 11.20% and a year to date share price return of 24.68%. However, the 1 year total shareholder return of a...

Capgemini (ENXTPA:CAP) has drawn fresh attention after reporting 2025 earnings, issuing 2026 revenue guidance of around 6.5% to 8.5% growth at constant exchange rates, and outlining a recommended €3.40 per share dividend. See our latest analysis for Capgemini. The earnings release, 2026 guidance and new cloud and AI partnerships with Microsoft, AWS and Google Cloud come as momentum in the shares has weakened, with a 30 day share price return of 28.18% and a 1 year total shareholder return of...

Rexel (ENXTPA:RXL) has given investors a packed update that combines full-year 2025 earnings, fresh 2026 sales guidance, a maintained cash dividend proposal and confirmation of completed share buybacks. See our latest analysis for Rexel. The latest update appears to have kept interest in Rexel alive, with the share price at €36.6 and a 30-day share price return of 6.33% and a 90-day share price return of 19.69%, alongside a 1-year total shareholder return of 44.40%. Taken together, these...

Eiffage (ENXTPA:FGR) is in focus after its Spanish subsidiary, Eiffage Energia Sistemas, secured more than €80 million in contracts to build onshore wind farm infrastructure for Capital Energy in Castile and Leon. See our latest analysis for Eiffage. Eiffage’s latest contracts in Spain land at a time when momentum in the shares has been strong, with a 30 day share price return of 15.87% and a 1 year total shareholder return of 58.67%, which points to growing optimism about the company’s...

Publicis Groupe (ENXTPA:PUB) has launched a share buyback program of up to €175 million, starting 13 February 2026. The program is intended to cover existing employee share-based incentives without issuing new shares. See our latest analysis for Publicis Groupe. Despite the buyback announcement and recent initiatives such as the proposed 2025 cash dividend of €3.75 per share and the launch of the Influential Sports unit, Publicis Groupe’s 30 day share price return of 15.69% and year to date...

What the latest trading statement tells you about Neurones Neurones (ENXTPA:NRO) just reported unaudited 2025 figures, with revenue of €857.2 million for the year and €225 million in Q4, and a higher operating margin in the second half. See our latest analysis for Neurones. Despite the stronger 2025 trading statement, the recent performance has been weak, with a 30 day share price return showing a 13.7% decline and a 1 year total shareholder return indicating a 22.5% loss, which suggests...

Assystem (EPA:ASY) has had a rough week with its share price down 8.5%. But if you pay close attention, you might find...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

The board of Signaux Girod S.A. ( EPA:ALGIR ) has announced that it will pay a dividend on the 9th of April, with...

Why Sartorius Stedim Biotech is Back on Investors’ Radar Sartorius Stedim Biotech (ENXTPA:DIM) recently issued 2026 sales growth guidance of around 5% to 9%, providing a fresh data point that gives investors a clearer anchor for expectations after a difficult few years. See our latest analysis for Sartorius Stedim Biotech. The 4.01% 1 day share price return to €174.95 came after the 2026 sales growth guidance and followed a 17.98% 30 day share price decline. The 5 year total shareholder...

In the past week, Renault attracted attention ahead of its 18 February 2026 earnings report, as investors focused on potential margin recovery in its electric vehicle and financing businesses. This renewed interest highlights how quickly sentiment can shift when a company’s profitability in newer segments, such as EVs and financial services, appears poised for change. We’ll now examine how this optimism around electric vehicle margin recovery could influence Renault’s broader investment...

If you are wondering whether Compagnie de Saint-Gobain shares offer solid value at around €90.86, the key is to look past the headline price and focus on how the market is actually pricing the business. The stock has returned 2.9% over the past week and 8.2% over the past month, while the 1 year return sits at a 3.9% decline and the 3 year and 5 year returns are 81.5% and 141.0% respectively. This gives a mixed picture for anyone trying to judge risk and reward. Recent news coverage around...

Sanofi (ENXTPA:SAN) announced that its Board of Directors will not renew CEO Paul Hudson's mandate. Belén Garijo, former Merck KGaA CEO and previous Sanofi executive, has been appointed as the incoming CEO. The leadership change comes at a time of R&D, productivity, and US vaccine business challenges for the company. Sanofi sits at the crossroads of big pharma and vaccines, with investors watching closely as it responds to recent pipeline setbacks and pressure in its US vaccine operations...

Why Danone stock is back on investors’ radar Danone (ENXTPA:BN) is drawing fresh attention after recent share price swings, with the stock roughly flat over the past day but showing mixed moves over the past week, month, and past 3 months. See our latest analysis for Danone. Zooming out, Danone’s recent 7 day share price return of 4.57% comes after a softer patch, with a 90 day share price return of 7.59%. Meanwhile, the 1 year total shareholder return of 10.78% and 3 year total shareholder...

What the latest guidance means for Soitec’s revenue outlook Soitec (ENXTPA:SOI) has put fresh numbers on the table, pairing a sharp year-on-year Q3 revenue drop with an outlook for around 20% revenue growth in Q4 2026 versus the previous quarter at constant exchange rates and scope. For you as an investor, that mix of weak annual comparison and sequential improvement, along with the new guidance, provides a basis for reassessing how the market might be thinking about the company’s earnings...

Why the CEO change at ERAMET (ENXTPA:ERA) matters for shareholders Eramet’s Board removed Chief Executive Officer Paulo Castellari on February 1, citing differences in operating methods, and appointed Chairwoman Christel Bories as interim CEO while a search process for a permanent replacement continues. For you as a shareholder or potential investor, sudden leadership changes can raise questions about execution, capital allocation and how consistently current projects, such as the lithium...

Schneider Electric (ENXTPA:SU) is back in focus after a run of product news, including EcoStruxure Foxboro Software Defined Automation, presented as the industry’s first open, software-defined distributed control system for complex industrial operations. See our latest analysis for Schneider Electric. These automation and grid software launches have arrived alongside firm share price momentum, with Schneider Electric’s €262.9 stock posting an 11.8% 1 month share price return and a 124.83% 5...

Airbus (ENXTPA:AIR) is back in focus after Air Canada confirmed a firm order for eight A350-1000 widebody jets, a sizeable long-haul commitment that underscores ongoing demand for next generation widebody aircraft. See our latest analysis for Airbus. At a share price of €192.42, Airbus has seen a 1-day share price return of 1.05% and a 7-day share price return of 0.59%. Its 30-day and year-to-date share price returns are declines of 11.49% and 5.54%, respectively, even as recent widebody...

Safran has opened a major landing gear production plant in Morocco focused on Airbus A320 programs. The facility is designed to support global aerospace supply chains and use mainly decarbonized energy. The project is expected to create hundreds of local jobs and expand Safran's manufacturing footprint. Safran, listed as ENXTPA:SAF, is adding this Moroccan plant at a time when its shares trade around €332.8. The company has seen share price returns of 8.1% over the past week and 36.8% over...

Eutelsat Communications (ENXTPA:ETL) H1 2026 Results: Losses Persist as Revenue Holds Just Below Prior Levels Eutelsat Communications (ENXTPA:ETL) has reported H1 2026 results with total revenue of €637.5 million and a basic EPS loss of €0.44, alongside trailing twelve month revenue of €1.23 billion and a basic EPS loss of €0.85. The company has seen revenue move from €640.4 million in H2 2024 to €606.2 million in H1 2025 and then to €637.5 million in H2 2025, while basic EPS has stayed in...